OPM on the move?

Woops,
meant to add the following
OPTUM GROUP LIMITED 2002-08-06 ASX-SIGNAL-G

HOMEX - Perth

+++++++++++++++++++++++++
PLACEMENT AND RESTRUCTURE INITIATIVES

Optum Group Limited ("Optum or Company") is pleased to announce the
completion of a placement of 24,507,075 fully paid ordinary shares
to clients of Bell Potter Securities Limited. The placement is to be
completed at a price of 0.6 cents per share to raise approximately
$147,000 before costs. The placees will also make available to Optum
a short term debt funding facility of $100,000. An Appendix 3B is
attached.

As part of the placement process, Mr Peter Jermyn will join the board
of Optum with current director, Mr Robert King stepping aside as
director. Mr King will remain in the management team. Mr Jermyn has
been involved in a number of public company initiatives which have
resulted in the successful commercialisation of a number of emerging
and growth industry opportunities.

PROPOSED SHARE CONSOLIDATION, RENOUNCEABLE RIGHTS ISSUE AND DEBT
RESTRUCTURING

The Company also proposes to proceed with, subject to obtaining all
necessary shareholder approvals, a one (1) for ten (10) share
consolidation followed by a five (5) for (2) renounceable rights
issue to existing shareholders. Funds raised by the placement and
the rights issue will be utilised to:

(a) continue to commercialise the Company's current pathology
transaction system, "Telepathy";

(b) investigate additional opportunities in the medical and
healthcare products and services industry.

The Company will shortly despatch a notice of meeting and explanatory
memorandum seeking, amongst other things, shareholder approval to
consolidate it's share capital on a one (1) for ten (10) basis such
that the total issued capital post consolidation will be
approximately 18.79m ordinary fully paid shares. Following approval
for theshare consolidation, the Company intends to proceed with a
five (5) for two (2) renounceable rights issue at an issue price of 5
cents per share (with a free attaching option exerciseable at 10
cents on or before 31 December 2004 for every two (2) shares
subscribed for) to raise approximately $2.35 million through the
issue of up to 46.9 million shares and 23.45 million options (on a
post consolidated basis).

The funds raised will be utilised to retire debt and progress with
the initiatives set out above. It is also anticipated that the
considerable corporate experience of the new board member will assist
in securing underwriting commitments for the proposed rights issue.

As part of the placement process, Albert Ho (and his related entities
Flandron Pty Ltd and Mediplus Management Pty Ltd) have agreed to
reduce current debts owing by the Company from approximately $1.22m
to $800,000. Flandron will also assign $400,000 of its existing
convertible note debt (representing half of the reduced $800,000
outstanding amount) to the entities participating in the placement.
The debt restructuring represents a significant saving to the
Company. In addition, Flandron and the assignees of the convertible
note have agreed not to demand repayment of any monies outstanding
until after the completion of the proposed rights issue referred to
above.

The inclusion of Mr Jermyn will provide Optum with a significant
opportunity to maximise commercial exposure of its existing pathology
transaction system, "Telepathy", and further investigate other
complimentary opportunities in the medical and health products and
services industry.

Dr A Ho
EXECUTIVE CHAIRMAN

MORE TO FOLLOW

OPTUM GROUP LIMITED 2002-08-06 ASX-SIGNAL-G

HOMEX - Perth

+++++++++++++++++++++++++
APPENDIX 3B
NEW ISSUE ANNOUNCEMENT

APPLICATION FOR QUOTATION OF ADDITIONAL SECURITIES AND AGREEMENT

Information or documents not available now must be given to ASX as
soon as available. Information and documents given to ASX become
ASX's property andmay be made public.

Introduced 1/7/96. Origin Appendix 5. Amended 1/7/98, 1/9/99,
1/7/2000.

Name of Entity
Optum Group Limited

ACN or ARBN
63 001 287 510

We (the entity) give ASX the following information.


PART 1 - ALL ISSUES
You must complete the relevant sections (attach sheets if
there is not enough space).



1. Class of securities issued Fully Paid Ordinary Shares
or to be issued (quoted)

2. Number of securities issued 24,507,075 fully paid
or to be issued (if known) ordinary shares
or maximum number which
may be issued

3. Principal terms of the securities Fully paid ordinary shares
(eg, if options, exercise price
and expiry date; if partly paid
securities, the amount
outstanding and due dates for
payment; if convertible securities,
the conversion price and dates
for conversion)

4. Do the securities rank equally Yes
in all respects from the date
of allotment with an existing
class of quoted securities

If the additional securities
do not rank equally, please
state:
* the date from which they do
* the extent to which they
participate for the next
dividend, (in the case of
a trust, distribution) or
interest payment
* the extent to which they do
not rank equally, other than
in relation to the next
dividend, distribution or
interest payment

5. Issue price or consideration $147,042 (at 0.6 cents per
share)

6. Purpose of the issue (if To fund sales and marketing
issued as consideration for initiatives for the Company's
the acquisition of assets, pathology transaction system
clearly identify those "Telepathy" and investigate
assets) other opportunities in the
medical and health products
and services industry

7. Dates of entering securities On or before 07/08/2002
into uncertified holdings
or despatch of certificates

NUMBER CLASS
8. Number and class of all 187,887,656 Ordinary fully paid
securities quoted on shares
ASX (including the 33,500,000 Options exercisable
securities in clause on or before 30/06/2005
2 if applicable) at 20 cents each

NUMBER CLASS
9. Number and class of all 17,8000,000 Options exercisable on
securities not quoted or before 28/09/2003
on ASX (including the at 10 cents each
securities in clause 2 1,000,000 Options exercisable on
if applicable) or before 30/06/2003
at 0.0001 cents each
3,000,000 Options exercisable on
or before 30/06/2005
at 20 cents each

10.Dividend policy (in the case Participation available from
of a trust, distribution the date of issue
policy) on the increased
capital (interests)

PART 2 - BONUS ISSUE OR PRO RATA ISSUE

Items 11 to 33 are Not Applicable

PART 3 - QUOTATION OF SECURITIES
You need only complete this section if you are applying for quotation
of securities


34. Type of securities (tick one)

(a) X Securities described in Part 1

(b) All other securities

Example: restricted securities at the end of the escrowed period,
partly paid securities that become fully paid, employee incentive
share securities when restriction ends, securities issued on expiry
or conversion of convertible securities

Entities that have Ticked Box 34(a)

Additional Securities Forming a New Class of Securities
(If the additional securities do not form a new class, go to 43)

Tick to indicate you are providing the information or documents

35. If the securites are equity securities, the names of
the 20 largest holders of the additional securities,
and the number and percentage of additional securities
held by those holders

36. If the securites are equity securities, a distribution
schedule of the additional securities setting out the
number of holders in the categories
1- 1,000
1,001 - 5,000
5,001 - 10,000
10,001 - 100,000
100,001 - and over

37. A copy of any trust deed for the additional securities
(now go to 43)

Entities that have Ticked Box 34 (b)

Items 38 to 42 are Not Applicable

ALL ENTITIES

Fees

43. Payment method (tick one)

Cheque attached

Electronic payment made
Note: Payment may be made electronically if Appendix 3B is
given to ASX electronically at the same time.

Periodic payment as agreed with the home branch has been
arranged
Note: Arrangements can be made for employee incentive
schemes that involve frequent issues of securities.

QUOTATION AGREEMENT

1. Quotation of our additional securities is in ASX's absolute
discretion. ASX may quote the securities on any conditions it
decides.

2. We warrant the following to ASX.

* The issue of the securities to be quoted complies with the
complies with the law and is not for an illegal purpose.

* There is no reason why those securities should not be granted
quotation.

* An offer of the securities for sale within 12 months after
their issue will not require disclosure under section 707(3)
or section 1012C(6) of the Corporations Act.

* Section 724 or section 1016E of the Corporations Act does not
apply to any applications received by us in relation to any
securities to be quoted and that no-one has any right to
return any securities to be quoted under sections 737, 738 or
1016F of the Corporations Act at the time that we request that
the securities be quoted.

* We warrant that if confirmation is required under section
1017F of the Corporations Act in relation to the securities to
be quoted, it has been provided at the time that we request
that the securities be quoted.

* If we are a trust, we warrant that no person has the right to
return the securities to be quoted under section 1019B of the
Corporations Act at the time that we request that the
securities be quoted.

3. We will indemnify ASX to the fullest extent permitted by law in
respect of any claim, action or expense arising from or connected
with any breach of the warranties in this agreement.

4. We give ASX the information and documents required by this form.
If any information or document not available now, will give it to
ASX before quotation of the securities begins. We acknowledge that
ASX is relying on the information and documents. We warrant that
they are (will be) true and complete.


A Ho
EXECUTIVE CHAIRMAN
06/08/2002